Smoking rates among individuals with mental illness are markedly higher than in the general population, with 25 percent of U.S. adults with any mental illness being current smokers. Serious mental illnesses show even higher prevalence, notably in schizophrenia and bipolar disorder. The FDA's 2022 proposal aims to reduce nicotine content in cigarettes to minimize addiction levels, aiming for transformative impact on tobacco control. Varenicline, or Chantix, is identified as the most effective treatment for cessation of smoking or nicotine vaping. Vaping is considered a potential harm-reduction strategy, though questions regarding its safety remain.
Among U.S. adults with any mental illness, 25 percent are current smokers—more than double the rate for those without mental illness. Patients with serious mental illness have substantially elevated smoking rates, with schizophrenia rates as high as 80 to 90 percent.
In 2022, the U.S. Food and Drug Administration proposed a landmark public health policy mandating the reduction of nicotine content in cigarettes to minimally addictive levels, which, if implemented, could drastically lower cigarette consumption.
Varenicline (Chantix) is currently recognized as the most effective cessation treatment for cigarette smoking or nicotine vaping, providing a targeted approach to nicotine addiction.
While vaping has been proposed as a harm-reducing treatment for adult cigarette smokers, there remain unanswered questions about its long-term effects and overall safety compared to traditional smoking.
Collection
[
|
...
]